Artwork

Conteúdo fornecido por TrialSite News. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por TrialSite News ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Player FM - Aplicativo de podcast
Fique off-line com o app Player FM !

Irfan Khan, M.D. Talks About Virtual Healthcare in Clinical Trials and Research Post COVID-19

17:20
 
Compartilhar
 

Manage episode 297076287 series 2949236
Conteúdo fornecido por TrialSite News. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por TrialSite News ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

Irfan Khan, M.D. talks about COVID-19 and the effect it will have on clinical trials, CROs, IROs, and research.

Dr. Khan goes over new capabilities that sites need to develop, be it virtual, home healthcare, or flexibility, and more, in order to stay competitive and keep high patient participation.

Below is a summary of the questions he answers in this podcast:

  • What is an Integrated Research Organization (IRO) and how is Circuit Clinical positioned in this space?
  • What did Circuit do to accommodate for Trial Continuity during COVID19?
  • Can you describe what virtual engagement means to Circuit?
  • What can Sponsors and CRO's do to help prevent participants from dropping out of studies and improve engagement?
  • Do research sites need a stimulus for business to continue after COVID-19?
  • Where do you see the future in clinical research going post-COVID-19 and what changes can the industry expect?
  • What's the best outcome that can happen post-COVID-19? What can industry stakeholders do to rescue their studies and get back on track?

You can learn more about Dr. Khan and Circuit Clinical here and here

  continue reading

82 episódios

Artwork
iconCompartilhar
 
Manage episode 297076287 series 2949236
Conteúdo fornecido por TrialSite News. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por TrialSite News ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

Irfan Khan, M.D. talks about COVID-19 and the effect it will have on clinical trials, CROs, IROs, and research.

Dr. Khan goes over new capabilities that sites need to develop, be it virtual, home healthcare, or flexibility, and more, in order to stay competitive and keep high patient participation.

Below is a summary of the questions he answers in this podcast:

  • What is an Integrated Research Organization (IRO) and how is Circuit Clinical positioned in this space?
  • What did Circuit do to accommodate for Trial Continuity during COVID19?
  • Can you describe what virtual engagement means to Circuit?
  • What can Sponsors and CRO's do to help prevent participants from dropping out of studies and improve engagement?
  • Do research sites need a stimulus for business to continue after COVID-19?
  • Where do you see the future in clinical research going post-COVID-19 and what changes can the industry expect?
  • What's the best outcome that can happen post-COVID-19? What can industry stakeholders do to rescue their studies and get back on track?

You can learn more about Dr. Khan and Circuit Clinical here and here

  continue reading

82 episódios

Minden epizód

×
 
Loading …

Bem vindo ao Player FM!

O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.

 

Guia rápido de referências